Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divarasib DDI Study with Itraconazole in Healthy Subjects
NCT06690138Phase 1Completed
- Sponsor
- Genentech
- Start
- Nov 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of divarasib in Solid tumors, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (2 arms), sponsored by Genentech. Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration-time Curve from Hour 0 to Last Measurable Concentration and 1 more. Started Nov 2024; status: completed.
02
Drugs
divarasib
03
Conditions
Solid tumorsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06690138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06690138.